These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31261257)

  • 1. Artificial Intelligence Estimates the Importance of Baseline Factors in Predicting Response to Anti-PD1 in Metastatic Melanoma.
    Indini A; Di Guardo L; Cimminiello C; De Braud F; Del Vecchio M
    Am J Clin Oncol; 2019 Aug; 42(8):643-648. PubMed ID: 31261257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
    Diem S; Kasenda B; Spain L; Martin-Liberal J; Marconcini R; Gore M; Larkin J
    Br J Cancer; 2016 Feb; 114(3):256-61. PubMed ID: 26794281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
    Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM
    Cancer Med; 2016 Oct; 5(10):2792-2799. PubMed ID: 27683208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
    Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
    Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
    Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
    Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
    Balatoni T; Ladányi A; Fröhlich G; Czirbesz K; Kovács P; Pánczél G; Bence E; Plótár V; Liszkay G
    Pathol Oncol Res; 2020 Jan; 26(1):317-325. PubMed ID: 30225783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.
    van der Kooij MK; Joosse A; Speetjens FM; Hospers GA; Bisschop C; de Groot JW; Koornstra R; Blank CU; Kapiteijn E
    Acta Oncol; 2017 Jan; 56(1):101-103. PubMed ID: 27911126
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
    Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM
    Melanoma Res; 2018 Dec; 28(6):571-577. PubMed ID: 30067547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.
    Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM
    Ann Oncol; 2019 Aug; 30(8):1370-1380. PubMed ID: 31150059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.
    Teterycz P; Jagodzińska-Mucha P; Cybulska-Stopa B; Mariuk-Jarema A; Kozak K; Koseła-Paterczyk H; Czarnecka AM; Rajczykowski M; Dziura R; Galus Ł; Mackiewicz J; Świtaj T; Klimczak A; Falkowski S; Suwiński R; Ziobro M; Ługowska I; Rutkowski P
    Melanoma Res; 2018 Oct; 28(5):435-441. PubMed ID: 29782381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
    Alexander M; Mellor JD; McArthur G; Kee D
    Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of neutrophil to lymphocyte ratio in advanced melanoma treated with anti-programmed death-1 therapy.
    Minowa T; Kato J; Hida T; Horimoto K; Sato S; Sawada M; Uhara H
    J Dermatol; 2018 Sep; 45(9):e250-e251. PubMed ID: 29572922
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.
    Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim K; Hwu WJ; McIntyre S; Hwu P
    Cancer Invest; 2008 Jul; 26(6):624-33. PubMed ID: 18584354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
    Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
    Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
    Dimitriou F; Zaremba A; Allayous C; Kähler KC; Gerard CL; Festino L; Schäfer S; Toussaint F; Heinzerling L; Hassel JC; Ascierto PA; Michielin O; Hauschild A; Lebbe C; Livingstone E; Ramelyte E; Cheng PF; Dummer R; Mangana J
    Eur J Cancer; 2021 May; 149():37-48. PubMed ID: 33823361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Roncati L
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.